Skip to main content
Clinical Trials/EUCTR2018-001082-17-HU
EUCTR2018-001082-17-HU
Active, not recruiting
Phase 1

A randomized, observer-blinded, active-controlled, Phase IIIb study to compare IV / Oral delafloxacin fixed-dose monotherapy with best available treatments in a microbiologically enriched population with surgical site infections - DRESS - DELAFLOXACIN INTRAVENOUS AND ORAL MONOTHERAPY

MENARINI RICERCHE S.p.A.0 sites600 target enrollmentJune 6, 2019

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Acute Bacterial Skin and Skin Structure Infection
Sponsor
MENARINI RICERCHE S.p.A.
Enrollment
600
Status
Active, not recruiting
Last Updated
5 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 6, 2019
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
MENARINI RICERCHE S.p.A.

Eligibility Criteria

Inclusion Criteria

  • 1\. Male or female patients aged more than 18 years.
  • 2\. Patients with a history of cardiothoracic / related leg or abdominal surgery, occurred within 30 days and no implant is left in place, and a diagnosis of SSI according to the CDC definition1, namely:
  • \- Superficial Incisional Surgical Site Infection, involving only skin and subcutaneous tissue of the incision, and at least one of the following local findings:
  • · purulent drainage from the superficial incision;
  • · organisms isolated from an aseptically obtained culture of fluid or tissue from the superficial incision;
  • · superficial incision is deliberately explored by surgeon AND the patient has at least one of the following signs or symptoms of infection:
  • \* pain or tenderness,
  • \* localized swelling,
  • \* redness or heat;
  • · diagnosis of superficial incisional SSI made by the Investigator.

Exclusion Criteria

  • 1\. Previous IV antimicrobial therapy exceeding 24 hour duration administered during 72 hours prior to the first dose of study treatment.
  • 2\. Any infection expected to require systemic antimicrobial agents other than study treatment(s)
  • 5\. Medical history of myasthenia gravis.
  • 6\. Medical history of C. difficile diarrhea.
  • 8\. Organ\-space infection.
  • 13\. Use of systemic corticosteroids for more than 10 days at a dose equivalent to more than 15 mg prednisolone in the previous 2 weeks.
  • 14\. Patients with end\-stage renal disease on hemodialysis or peritoneal dialysis or creatinine clearance (CrCl) \< 15 mL/min using the Cockcroft\-Gault formula.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Study to compare Delafloxacin intravenous and oral single drug therapy with best available treatments in patients with surgical site infectionsAcute Bacterial Skin and Skin Structure InfectionMedDRA version: 20.1Level: PTClassification code 10052891Term: Skin bacterial infectionSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
EUCTR2018-001082-17-ATMENARINI RICERCHE S.p.A.600
Active, not recruiting
Phase 1
Study to compare Delafloxacin intravenous and oral single drug therapy with best available treatments in patients with surgical site infectionsAcute Bacterial Skin and Skin Structure InfectionMedDRA version: 20.1Level: PTClassification code 10052891Term: Skin bacterial infectionSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
EUCTR2018-001082-17-CZMENARINI RICERCHE S.p.A.600
Active, not recruiting
Phase 1
Study to compare Delafloxacin intravenous and oral single drug therapy with best available treatments in patients with surgical site infectionsAcute Bacterial Skin and Skin Structure InfectionMedDRA version: 20.1Level: PTClassification code 10052891Term: Skin bacterial infectionSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
EUCTR2018-001082-17-ROMENARINI RICERCHE S.p.A.266
Active, not recruiting
Phase 1
Study to compare Delafloxacin intravenous and oral single drug therapy with best available treatments in patients with surgical site infectionsAcute Bacterial Skin and Skin Structure InfectionMedDRA version: 20.1Level: PTClassification code 10052891Term: Skin bacterial infectionSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
EUCTR2018-001082-17-HRMENARINI RICERCHE S.p.A.600
Active, not recruiting
Phase 1
Study to compare Delafloxacin intravenous and oral single drug therapy with best available treatments in patients with surgical site infectionsAcute Bacterial Skin and Skin Structure InfectionMedDRA version: 20.1Level: PTClassification code 10052891Term: Skin bacterial infectionSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
EUCTR2018-001082-17-GBMENARINI RICERCHE S.p.A.600